Ability of vaccinee sera to mediate ADCC activity.

<p>CEMNK^r target cells were pulsed with gp120 prior to exposure of vaccine serum at a 1∶100 dilution. Target cell lysis indicates the ability of vaccinee serum to mediate cell killing by PBMC from a normal human donor. Dotted line indicates background cell lysis observed with a normal human sera control.</p

Profiles of antibody responses elicited by three HIV vaccine regimens.

<p>Profiles of antibody responses elicited by three HIV vaccine regimens.</p

Analysis of antibodies against CD4 inducible (CD4i) epitopes.

<p>A) The presence of co-receptor binding site-directed antibodies was assayed by competition with the mAb, 17b. Competition titer indicates the serum dilution capable of outcompeting 50% of pseudoviral binding to 17b. B) Neutralizing antibody titers against HIV-1 JR-FL isolate without sCD4 treatment. C) Neutralizing antibody titers against HIV-1 JR-FL isolate with sCD4 treatment. D) Effect of V3 peptide treatment on neutralizing activity against sCD4-treated JR-FL.</p

The ability of Env-specific antibodies to activate the complement cascade present in complement intact normal human sera was determined using deposition of C4 as a marker for complement activation.

<p>A representative plot with data from a single individual from each trial is shown. A) gp120-specific IgG measurement and B) C4 detection in the same testing sera.</p

Summary of vaccine regimens.

<p># QS-21 & 3D-MPL in o/w emulsion.</p><p>*A: 92UG037 B: 92US715 Bal: Ba-L C:96ZM651 E: 93TH976.</p

Specificity of vaccine-induced antibody responses as determined through mAb competition.

<p>The ability of serially diluted human immune serum to outcompete binding of mAb to a JR-FL & VSV-G pseudotyped virus was measured. Competition titers indicate the serum dilution preventing 50% of pseudoviral binding to the mAb. A) Competition with carbohydrate-specific mAb, 2G12. B) Competition with V3 loop-specific mAb, 447-52D. C) Competition with CD4bs-specific mAb, b12.</p

Confirmation of neutralizing activities against representative HIV isolates.

<p>Neutralization antibody titers at 50% inhibition for each serum are shown against either SF162 (A) or SS1196.1 (B). Neutralizing activities against SC422661.8 (C) is shown as the fractions of individual sera from each trial either capable of achieving at least 50% inhibition of infection at a 1∶10 serum dilution (shaded portion) or unable to achieve 50% inhibition (open portion). All p values reaching significance (p<0.05) are presented in the figure. All other comparisons did not reach significant based upon Kruskal-Wallis and Dunn'significance tests.</p

Post-Infection Breadth of T-Cell Response.

<p>Breath of the post-infection T-cell response as measured by IFNγ ELISpot, as quantified by the number of reactive 15-mers, for the vaccine (grey) and placebo (black) groups. The distribution of breadth is shown for all proteins in aggregate; for Gag, Pol, and Nef combined; for other non-insert proteins; and for Gag, Pol, and Nef individually. The p-values refer to tests comparing breadth between vaccine and placebo groups.</p

Post-Infection Magnitude of CD8+ T-Cell Response.

<p>Magnitude of the post-infection CD8+ T-cell response measured by ICS, as quantified by the percentage of CD8+ T-cells producing IFN or IL-2 when stimulated with the vaccine-insert-matched peptide pools (Gag, Pol, and Nef) and other non-vaccine-insert peptide pools, for vaccine and placebo groups. Positive responses are indicated using closed red circles and negative responses using open blue circles. The p-values refer to tests comparing response magnitudes between the vaccine and placebo positive responders.</p

Acute Log₁₀ Viral Load.

<p>The distribution of acute log₁₀ viral load values in vaccine and placebo groups. Solid lines correspond to observed means and dashed lines correspond to means estimated using the multiple imputation approach.</p